Böbrek Kanserinde Yüksek Yoğunlukta Odaklanmış Ultrason İle Ablasyon
Özet
Yüksek yoğunluklu odaklanmış ultrason (HIFU), dokuların derinliklerindeki lokalize tümör bölgelerini hedef alan invazif olmayan ve iyonize olmayan modern bir termal ablasyon yöntemidir. Cilt ve çevre dokulara zarar vermeden odaklanan bu teknoloji, hedef bölgedeki sıcaklığı 55 °C'nin üzerine çıkararak koagülasyon nekrozu yoluyla hücre ölümünü sağlar. Ayrıca yüksek yoğunluklu akustik dalgalarla tetiklenen kavitasyon gibi mekanik etkiler de hücre apoptozisinde rol oynar. HIFU tedavisi; ameliyat riski yüksek hastalarda düşük enfeksiyon riski, daha az anestezi ihtiyacı, minimal postoperatif ağrı ve hızlı iyileşme gibi önemli avantajlar sunmaktadır. Bununla birlikte, hasta hareketlerine karşı duyarlılık, uzun tedavi süreleri, cilt yanıkları, vazospazm ve nadir kanama riskleri yöntemin başlıca limitasyonlarıdır. Küçük böbrek kitlelerinde nefrektomiye alternatif olarak araştırılan HIFU, literatürdeki çeşitli faz çalışmaları ve transplante böbreklerde gelişen renal hücreli kanser vakalarında değerlendirilmiştir. Mevcut kılavuzlarda eşlik eden hastalığı fazla olan düşkün hastalar için zayıf dereceyle önerilen bu yöntemin, ablasyon başarısını etkileyen cilt altı ve perinefritik yağ dokusu kalınlığı gibi faktörleri bulunmaktadır. Günümüzde altın standart cerrahi olsa da HIFU, seçilmiş vakalarda güvenli bir alternatif sunmaktadır ancak yaygın klinik kullanımı için geniş popülasyonlu çalışmalara ihtiyaç duyulmaktadır.
High-intensity focused ultrasound (HIFU) is a non-invasive and non-ionizing thermal ablation method targeting localized tumor areas deep within tissues. By focusing ultrasound waves without damaging the skin and surrounding tissues, it raises the target tissue temperature above 55 °C, inducing cell death via coagulation necrosis. Mechanical effects such as cavitation, triggered by high-intensity acoustic pulses, also contribute to cellular apoptosis. For high-risk surgical patients, HIFU offers critical advantages including lower infection risks, reduced anesthesia requirements, minimal postoperative pain, and rapid recovery periods. However, its main limitations include sensitivity to patient movement, prolonged treatment durations, and risks of skin burns, vasospasm, or rare hemorrhages. Investigated as an alternative to nephrectomy for small renal masses, HIFU has been evaluated in several phase studies and cases of renal cell carcinoma in transplanted kidneys. Currently recommended with a weak strength for frail patients with multiple comorbidities in clinical guidelines, its ablation efficacy is influenced by factors like subcutaneous and perinephric fat thickness. Although surgery remains the gold standard, HIFU serves as a viable, safe alternative for selected cases, though extensive large-population studies are required before widespread clinical adoption.
Referanslar
Lafon C, Melodelima D, Salomir R, Chapelon JY. Interstitial devices for minimally invasive thermal ablation by high-intensity ultrasound. Int J Hyperthermia. 2007 Mar;23(2):153-63.
Jolesz FA. MRI-guided focused ultrasound surgery. Annu Rev Med. 2009;60:417-30.
Cline HE, Hynynen K, Watkins RD, Adams WJ, Schenck JF, Ettinger RH, Freund WR, Vetro JP, Jolesz FA. Focused US system for MR imaging-guided tumor ablation. Radiology. 1995 Mar;194(3):731-7.
Hynynen K, Darkazanli A, Unger E, Schenck JF. MRI-guided noninvasive ultrasound surgery. Med Phys. 1993 Jan-Feb;20(1):107-15.
Zhou YF. High intensity focused ultrasound in clinical tumor ablation. World J Clin Oncol. 2011 Jan 10;2(1):8-27.
Haar GT, Coussios C. High intensity focused ultrasound: physical principles and devices. Int J Hyperthermia. 2007 Mar;23(2):89-104.
ter Haar G, Rivens I, Chen L, Riddler S. High intensity focused ultrasound for the treatment of rat tumours. Phys Med Biol. 1991 Nov;36(11):1495-501.
Dewey WC, Diederich CJ, Dewhirst MW. Hyperthermia classic commentary: 'Arrhenius relationships from the molecule and cell to the clinic' by William Dewey, Int. J. Hyperthermia, 10:457-483, 1994. Int J Hyperthermia. 2009 Feb;25(1):21-4.
Lagneaux L, de Meulenaer EC, Delforge A, Dejeneffe M, Massy M, Moerman C, Hannecart B, Canivet Y, Lepeltier MF, Bron D. Ultrasonic low-energy treatment: a novel approach to induce apoptosis in human leukemic cells. Exp Hematol. 2002 Nov;30(11):1293-301.
Miller DL, Smith NB, Bailey MR, Czarnota GJ, Hynynen K, Makin IR; Bioeffects Committee of the American Institute of Ultrasound in Medicine. Overview of therapeutic ultrasound applications and safety considerations. J Ultrasound Med. 2012 Apr;31(4):623-34.
Hynynen K, Chung AH, Colucci V, Jolesz FA. Potential adverse effects of high-intensity focused ultrasound exposure on blood vessels in vivo. Ultrasound Med Biol. 1996;22(2):193-201.
Ljungberg, B., et al., EAU Guidelines on Renal Cell Carcinoma 2021, in European Association of Urology Guidelines. 2021 Edition. 2021, European Association of Urology Guidelines Office: Arnhem, The Netherlands.
K.U. Köhrmann, M.S. Michel, J. Fruhauf, J. Volz, W. Back, J. Gaa, et al. High intensity focused ultrasound for non-invasive tissue ablation in the kidney, prostate and uterus. J. Urol., 163 (Suppl.) (2000), p. 156.
Illing RO, Kennedy JE, Wu F, ter Haar GR, Protheroe AS, Friend PJ, Gleeson FV, Cranston DW, Phillips RR, Middleton MR. The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population. Br J Cancer. 2005 Oct 17;93(8):890-5.
Ritchie RW, Leslie T, Phillips R, Wu F, Illing R, ter Haar G, Protheroe A, Cranston D. Extracorporeal high intensity focused ultrasound for renal tumours: a 3-year follow-up. BJU Int. 2010 Oct;106(7):1004-9.
Ritchie, R., et al., Attenuation and de-focusing during high-intensity focused ultrasound therapy through peri-nephric fat. 2013. 39(10): p. 1785-1793.
Chakera A, Leslie T, Roberts I, O'Callaghan CA, Cranston D. A lucky fall? Case report. Transplant Proc. 2010 Nov;42(9):3883-6.
Di Candio G, Porcelli F, Campatelli A, Guadagni S, Vistoli F, Morelli L. High-Intensity Focused Ultrasonography and Radiofrequency Ablation of Renal Cell Carcinoma Arisen in Transplanted Kidneys: Single-Center Experience With Long-Term Follow-Up and Review of Literature. J Ultrasound Med. 2019 Sep;38(9):2507-2513.
